Chemed (NYSE:CHE) Stock Price Expected to Rise, Bank of America Analyst Says

Chemed (NYSE:CHE) had its target price boosted by equities researchers at Bank of America from $450.00 to $510.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Bank of America‘s price target points to a potential upside of 6.38% from the stock’s previous close.

Other analysts also recently issued reports about the stock. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen cut shares of Chemed from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Weiss Ratings raised shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Finally, Royal Bank Of Canada increased their target price on shares of Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $480.25.

Chemed Stock Down 1.2%

Shares of Chemed stock opened at $479.39 on Thursday. The business has a fifty day simple moving average of $440.51 and a 200 day simple moving average of $427.90. The stock has a market cap of $6.36 billion, a PE ratio of 26.13, a price-to-earnings-growth ratio of 1.79 and a beta of 0.52. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11. Chemed has a 12 month low of $365.20 and a 12 month high of $492.30.

Chemed (NYSE:CHE) last issued its earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.30 by $0.35. The firm had revenue of $657.51 million for the quarter, compared to analysts’ expectations of $659.22 million. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The company’s revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $5.63 earnings per share. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Research analysts predict that Chemed will post 22.67 EPS for the current year.

Insider Buying and Selling

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the sale, the chief executive officer directly owned 90,219 shares of the company’s stock, valued at approximately $37,993,927.47. The trade was a 2.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Andrea R. Lindell sold 1,347 shares of the stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total value of $602,553.51. Following the transaction, the director owned 4,578 shares of the company’s stock, valued at approximately $2,047,876.74. This trade represents a 22.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 3.33% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Sunburst Financial Group LLC lifted its stake in Chemed by 12.0% in the 2nd quarter. Sunburst Financial Group LLC now owns 812 shares of the company’s stock valued at $378,000 after acquiring an additional 87 shares in the last quarter. First Heartland Consultants Inc. raised its holdings in shares of Chemed by 14.5% in the second quarter. First Heartland Consultants Inc. now owns 1,404 shares of the company’s stock valued at $654,000 after purchasing an additional 178 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Chemed by 149.0% in the second quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock worth $289,000 after purchasing an additional 371 shares in the last quarter. Somerset Trust Co acquired a new position in Chemed during the second quarter worth $228,000. Finally, MassMutual Private Wealth & Trust FSB grew its position in Chemed by 65.3% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company’s stock valued at $38,000 after purchasing an additional 32 shares in the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.